Female-led AMLo Biosciences snaps £2.45M for early-stage skin cancer test — TFN

AMLo Biosciences, a Newcastle University spin-out focused on early skin cancer detection, has secured £2.45 million in funding. The investment, led by Future Planet Capital, will support clinical trials and the launch of AMBLor, a prognostic test for early-stage melanomas. The funding round also included investments from Ascension's Life Fund, Conduit's EIS Impact Fund, and existing investors like NorthStar Ventures, Future Planet Capital's BIF Opportunities Fund, and Esperante. The company plans to launch AMBLor in the UK and US in 2022, followed by Australia in 2023.

AMLo Biosciences Raises £2.45 Million for Early Skin Cancer Detection Test

AMLo Biosciences is a Newcastle University spin-out med-tech startup specializing in the early detection of skin cancer. They offer a prognostic test for early-stage skin cancer that can accurately identify genuinely low-risk melanomas, aiming to provide evidence for inclusion in clinical guidelines and launching their AMBLor product in the UK and US in 2022.

A med-tech startup specializing in the early detection of skin cancer, offering a prognostic test for early-stage melanomas.

3 years ago

AMLo Biosciences Raises £2.45 Million for Early Skin Cancer Detection Test

Covered on